drugset / Trial / NCT00407043

Multicenter, Randomized, Controlled Study of the Effect of Lotemax on Initiation of Dry Eye Treatment With Restasis

NCT00407043

RandomizedParallel-groupDouble-blindTreatment

Summary

To evaluate the impact of Lotemax on the initiation of Restasis therapy in patients with dry eye. It is hypothesized that the anti-inflammatory activity of Lotemax may help mitigate the stinging with cyclosporine administration and the dry eye signs and symptoms experienced during the initiation of therapy.

Timeline

Start
2006-11
Primary completion
2007-09
Completion
2007-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Loteprednol Etabonate Other / unclassified 0.5 %
Background Cyclosporine Peptide 0.05 % Topical

Indications